Technology Appraisal Virtual Committee Meeting

Committee B

Zoom

# Minutes: Confirmed

## Date and Time: Wednesday 13 May 2020 10:00am – 6:30pm

### Present:

1. Professor Amanda Adler (Chair) Present for all notes
2. Dr Sanjeev Patel (Vice-Chair) Present for all notes
3. Dr Carlo Berti Present for all notes
4. Dr Laura Bojke Present for all notes
5. Mr Mark Chapman Present for all notes
6. Dr Susan Faulds Present for all notes
7. Dr Mark Glover Present for notes 3 to 17
8. Dr Megan John Present for notes 1 to 14
9. Professor Sanjay Kinra Present for all notes
10. Dr Nicholas Latimer Present for all notes
11. Dr Veline L'Esperance Present for all notes
12. Dr Rhiannon Owen Present for all notes
13. Ms Anna Pracz Present for all notes
14. Dr Stephen Smith Present for all notes
15. Professor Nicky Welton Present for all notes
16. Mr Nigel Westwood Present for all notes
17. Professor Sarah Wild Present for all notes
18. Dr Ed Wilson Present for all notes
19. Dr Stuart Williams Present for notes 1 to 14
20. Mr Tony Wootton Present for all notes

### In attendance:

* Helen Knight, Programme Director, NICE, Present for all notes
* Linda Landells, Associate Director, NICE, Present for notes 1 to 6
* Nicole Elliott, Associate Director, NICE, Present for notes 1 and then 7 to 17
* Jeremy Powell, Project Manager, NICE, Present for notes 1 to 12
* Laura Marsden, Coordinator, NICE, Present for all notes
* Joanne Ekeledo, Project Manager, NICE, Present for notes 13 to 17
* Rashida Akhtar, Administrator, NICE, Present for notes 13 to 17
* Alan Moore, Technical Analyst, NICE, Present for notes 1 to 6
* Emily Eaton Turner, Technical Adviser, NICE, Present for notes 1 to 6
* Verena Wolfram, Technical Analyst, NICE, Present for notes 7 to 12
* Ross Dent, Technical Adviser, NICE, Present for notes 1 to 12
* Mary Hughes, Technical Analyst, NICE, Present for topic 13 to 17
* Carl Prescott, Technical Adviser, NICE, Present for topic 13 to 17
* Jenna Dilkes, Programme Manager, NICE, Present for all notes
* Natalie Spray, Project Manager, NICE, Present for all notes
* Mandy Brereton, Assistant Project Manager, NICE, Present for all notes
* Nick Lowe, Digital Services, NICE, Present for all notes
* Oswin Jackson, Digital Services, NICE, Present for all notes
* Professor Matt Stevenson, ScHARR, Evidence Review Group, Present for notes 1 to 4
* Dr John Stevens, ScHARR, Evidence Review Group, Present for notes 1 to 4
* Dr Emma Hock, ScHARR, Evidence Review Group, Present for notes 1 to 4
* Mr Alan Chant, Patient Expert, Trustee Myloma UK, Present for notes 1 to 4
* Shelagh McKinlay, Patient Expert, Head of Patient Advocacy, Myeloma UK, Present for notes 1 to 4
* Professor Gordon Cook, Clinical Expert, Consultant Haematologist, Present for notes 1 to 4
* Dr Neil Rabin, Clinical Expert, Consultant Haematologist, Present for notes 1 to 4
* Dr Miriam Brazzelli, Aberdeen HTA, Evidence Review Group, Present for notes 7 to 9
* Dr Graham Scotland, Aberdeen HTA, Evidence Review Group, Present for notes 7 to 9
* Dr Lorna Aucott, Aberdeen HTA, Evidence Review Group, Present for notes 7 to 9
* Dr Daniel Kopasker, Aberdeen HTA, Evidence Review Group, Present for notes 7 to 9
* Dr Sree Rodda, Clinical Expert, Consultant Clinical Oncologist, Present for notes 7 to 8
* Professor Nicholas James, Clinical Expert, Professor of Clinical Oncology, Present for notes 7 to 8
* Dr Stephen Allen, Patient Expert, Patient Representative for Tackle Prostate Cancer, Present for notes 7 to 8
* Ms Jane Hocking, Patient Expert, Specialist Nurse, Prostate Cancer UK, Present for notes 7 to 8
* Professor G.J. Melendez-Torres, Peninsula Technology Assessment Group, Evidence Review Group, Present for notes 13 to 14
* Mr David Scott, Peninsula Technology Assessment Group, Evidence Review Group, Present for notes 13 to 14
* Ms Caroline Farmer, Peninsula Technology Assessment Group, Evidence Review Group, Present for notes 13 to 14
* Dr Will Lester, Clinical Expert, Consultant Haematologist, Present for notes 13 to 14
* Professor Marie Scully, Clinical Expert, Professor of Haematology, Present for notes 13 to 14
* Mrs Jo McIntyre, Patient Expert, Founder TTPNetwork, Present for notes 13 to 14
* Mr Jamie Blackshaw, Patient Expert, Volunteer/Member TTPNetwork, Present for notes 13 to 14
* Ms Fiona Marley, Clinical Expert, NHS England Commissioning, Present for notes 13 to 14
* Professor Peter Clark, Cancer Drugs Fund Clinical Lead, Present for notes 1 to 4 and 7 to 12

### Non-public attendees

* Orsolya Balogh, Technical Analyst, NICE, Present for notes 7 to 8
* Helen Barnett, Medical Editor, NICE, Present for notes 7 to 17
* Jessica Cronshaw, Technical Analyst, NICE, Present for notes 1 to 4
* Eleanor Donegan, Technical Adviser, NICE, Present for notes 7 to 9
* Lorna Dunning, Technical Adviser, NICE, Present for notes 1 to 6
* Henry Edwards, Technical Advisor, Managed Access, NICE, Present for notes 7 to 12
* Emma Flood, Audience Insight Manager, NICE, Present for notes 1 to 4
* Yelan Gou, Technical Advisor, NICE, Present for notes 7 to 17
* Ann Greenwood, Senior Medical Editor, NICE, Present for notes 1 to 6
* Christine Harris, Project Manager, NICE, Present for notes 13 to 14
* Claire Hawksworth, Technical Adviser, Managed Access, NICE, Present for notes 1 to 4 and 13 to 17
* Farhaan Jamadar, Technical Analyst, NICE, Present for notes 13 to 14
* Theresa Jennison, Programme Manager, Quality Standards & Indicators, NICE, Present for notes 7 to 12
* Heidi Livingstone, Public Involvement adviser, NICE, Present for notes 1 to 4 and 13 to 14
* Edgar Masanga, RIA, NICE, Present for all notes
* Rosalee Mason, Corporate Office Coordinator, NICE, Present for notes 1 to 4, and 13 to 14
* Hannah Nicholas, Technical Analyst, NICE, Present for notes 1 to 6
* Anneka Patel, Project Manager, NICE, Present for notes 13 to 14
* Sandra Robinson, Corporate Office Coordinator, NICE, Present for notes 1 to 4, and 13 to 14
* Thomas Strong, Technical Adviser, Managed Access, NICE, Present for all notes

## Notes

### Any other Business

None.

### Minutes from the last meeting

1. The committee approved the minutes of the committee meeting held on Thursday 12 March 2020.

## Appraisal of isatuximab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma [ID1477]

### Part 1 – Open session

1. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG)/Assessment Group (AG) representatives and representatives from Sanofi.
2. The Chair asked all committee members, experts, ERG/AG representatives and NICE staff present to declare any relevant interests.   
   1. Professor Gordon Cook declared a direct financial interest as he has received consultancy fees from Sanofi, Janssen and Celgene. He also receives fees for giving talks at Janssen.
      1. It was agreed that this declaration would not prevent him from participating in this section of the meeting.
   2. Dr Neil Rabin declared a direct financial interest as he has received support from Celgene, Janssen-Cilag and Takeda to attend conferences, speak at educational meetings and advisory boards. He is also a member of advisory boards for Karyopharm and Amgen. He is an Executive member of UKMF.
      1. It was agreed that this declaration would not prevent him from participating in this section of the meeting.
   3. Mr Alan Chant declared an indirect professional interest as he is a trustee of Myeloma UK.
      1. It was agreed that this declaration would not prevent him from participating in this section of the meeting.
   4. Ms Shelagh McKinlay declared an indirect financial interest as she is employed by Myeloma UK and they receive funding from several pharmaceutical companies, including Amgen, Janssen and Celgene.
      1. It was agreed that this declaration would not prevent her from participating in this section of the meeting.
   5. Prior to the committee meeting Peter Wheatley-Price declared a direct financial interest as he works for Takeda who manufacture a potential competitor product for isatuximab.
      1. It was agreed that this declaration would prevent him from participating in this appraisal.
   6. No further conflicts of interest were declared for this appraisal.
   7. The Chair introduced the lead team, Dr Sanjeev Patel, Dr Nicholas Latimer and Mr Tony Wootton who gave presentations on the clinical effectiveness and cost effectiveness of the treatment.
   8. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

### Part 2 – Closed session (company representatives, clinical and patient experts, ERG/AG representatives and members of the public were asked to leave the meeting)

1. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) was discussed by the committee.
2. The committee decision was based on consensus.

1. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.

## Appraisal of enzalutamide with androgen deprivation therapy for treating metastatic hormone-sensitive prostate cancer [ID1605]

### Part 1 – Open session

1. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG)/Assessment Group (AG) representatives and representatives from Astellas.
2. The Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests  
   1. Professor Nicholas James declared an indirect financial interest as his previous institution has received funding for clinical trials. He also declared a direct financial interest for consultancy work and lecturing from Sanofi, Janssen, Astellas, Clovis and Bayer. He is also chief investigator on the STAMPEDE trials.
      1. It was agreed that this declaration would not prevent him from participating in this section of the meeting.
   2. Dr Stephen Allen declared an indirect financial interest as Tackle Prostate Cancer receive unrestricted funding from Astellas and Janssen.
      1. It was agreed that this declaration would not prevent him from participating in this section of the meeting.
   3. Ms Jane Hocking declared an indirect financial interest as Prostate Cancer UK have received funding for specific projects from Bayer and Janssen.

8.3.1 It was agreed that this declaration would not prevent her from participating in this section of the meeting.

* 1. Prior to the committee meeting Peter Wheatly Price declared a direct financial interest as he works for Takeda who manufacture a comparator product for enzalutamide.
     1. It was agreed that this declaration would prevent him from participating in this section of the meeting.
  2. No further conflicts of interest were declared for this appraisal.
  3. The Chair introduced the lead team, Dr Stuart Williams, Dr Ed Wilson and Mr Nigel Westwood who gave presentations on the clinical effectiveness and cost effectiveness of the treatment.
  4. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

### Part 2a – Closed session (company representatives and clinical and patient experts were asked to leave the meeting)

1. The committee discussed confidential information submitted as part of this appraisal.

### Part 2b – Closed session (ERG representatives were asked to leave the meeting)

1. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) was discussed by the committee.
2. The committee decision was based on consensus.
3. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.

## Appraisal of caplacizumab for treating adults experiencing an episode of acquired thrombotic thrombocytopenic purpura [ID1185]

### Part 1 – Open session

1. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG)/Assessment Group (AG) representatives and representatives from Sanofi.
2. The Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests  
   1. Dr Rhiannon Owen declared an indirect financial interest as she has previously received consultancy fees from Roche, the consultancy work ceased in June 2019.
      1. It was agreed that this declaration would not prevent her from participating in this appraisal.
   2. Dr Will Lester declared a direct financial interest as he has received honorarium for attending advisory board meetings for Sanofi.
      1. It was agreed that this declaration would not prevent him from participating in this section of the meeting.
   3. Professor Marie Scully declared direct financial interests as she has received honorarium for attending advisory board meetings for Sanofi and received fees for speaking engagements on TTP at Sanofi meetings and congresses.

14.3.1 It was agreed that this declaration would not prevent her from participating in this section of the meeting.

* 1. Prior to the meeting Peter Wheatley Price declared a direct financial interest as he works for Takeda who are in phase 3 of producing a potential competitor product for caplacizumab.

14.4.1 It was agreed that this declaration would prevent him from participating in this section of the meeting.

* 1. No further conflicts of interest were declared for this appraisal.

* 1. The Chair introduced the lead team, Dr Sanjay Kinra, Dr Nicky Welton and Mr Nigel Westwood who gave presentations on the clinical effectiveness and cost effectiveness of the treatment.
  2. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

### Part 2 – Closed session (company representatives, clinical and patient experts, ERG/AG representatives and members of the public were asked to leave the meeting)

1. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) was discussed by the committee.
2. The committee decision was based on consensus.
3. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.